| AdventHealth Research Institute

NCT05176483

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)

This study is currently enrolling.

You are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this study, you will receive an inv ...

NCT03683186

ADVANCE OUTCOMES - A Study Evaluating the Efficacy and Safety of Ralinepag To Improve Treatment Outcomes in PAH Patients

A research study is a scientific way to improve or develop new methods of health care. Studies are designed to answer specific questions on how to prevent, diagnose, or treat diseases and disorders. Many types of research studi ...

COMET: ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks.

This study is currently enrolling.

Study Purpose: To determine how working a nighttime shift impacts your metabolism. To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria: Study ...

NCT05064878

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.

The purpose of this informed consent form is to collect data about the non-paid caregiver of a subject that is participating in ZX008-2103 study. You, as the non-paid caregiver, are being asked to complete the EQ-5D-5L Quality ...

NCT05653271

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

$Icon for trial | ACE1831-001 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies$

This study is currently enrolling.

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

NCT05626634

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have completed study LP352-201. L ...

NCT05399888

Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia

This study is currently enrolling.

Alzheimer’s Disease (AD): The purpose of this study is to look at whether BIIB080 (the study drug) can help people with Alzheimer’s Disease (AD), how safe it is, and how the body handles taking it (known as tolerability). Parti ...

NCT05457556

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

This study looks at how well cabozantinib in combination with MAP work when given to children and young adults with newly diagnosed OST disease. Cabozantinib is experimental because it has not been proven to work in a situation ...

NCT04561362

BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies

This study is currently enrolling.

NCT05047263

FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.

Study Purpose: To determine the safety and efficacy of Finerenone along with standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease. To be enrolled in this study, you must m ...

Subscribe to

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)

ADVANCE OUTCOMES - A Study Evaluating the Efficacy and Safety of Ralinepag To Improve Treatment Outcomes in PAH Patients

COMET: ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks.

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies

FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.

Explore

Institutes